







What is claimed is:

1. A compound of the Formula IA, IB, IIA, IIB, IIIA or IIIB:



wherein:

R<sup>1</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl and benzyl, each of which is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, -CN, -OR<sup>8</sup> and -NR<sup>8</sup>R<sup>9</sup>;

R<sup>2</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl and C<sub>1</sub>-C<sub>6</sub> haloalkyl;

R<sup>3</sup> is selected from the group consisting of H, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>3</sub>-C<sub>6</sub> cycloalkyl, wherein C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>3</sub>-C<sub>6</sub> cycloalkyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from OR<sup>8</sup> and NR<sup>8</sup>R<sup>9</sup>;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each independently selected at each occurrence thereof from the group consisting of H, halogen, -OR<sup>10</sup>, -NO<sub>2</sub>, NR<sup>10</sup>R<sup>11</sup>, -NR<sup>10</sup>C(O)R<sup>11</sup>, -NR<sup>10</sup>C(O)NR<sup>11</sup>R<sup>12</sup>, -S(O)<sub>n</sub>R<sup>11</sup>, -CN, -C(O)R<sup>11</sup>, -C(O)<sub>2</sub>R<sup>11</sup>, -C(O)NR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl and C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, wherein each of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl and C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, =O, -CN, -OR<sup>8</sup>, -NR<sup>8</sup>R<sup>9</sup> and phenyl, and wherein phenyl is optionally substituted 1-3 substituents selected independently at each occurrence from halogen, -CN, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, -OR<sup>8</sup> and -NR<sup>8</sup>R<sup>9</sup>;

alternatively  $R^5$  and  $R^6$  are  $-O-C(R^{11})_2-O-$ ;

$R^7$  is selected from the group consisting of H, halogen and  $OR^{10}$ ;

$R^8$  and  $R^9$  are each independently selected from the group consisting of H,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl,  $C_1-C_4$  alkoxyalkyl,  $C_1-C_4$  alkoxyalkylalkyl,  $C_3-C_6$  cycloalkyl,  $C_4-C_7$  cycloalkylalkyl,  $-C(O)R^{12}$ , phenyl and benzyl, wherein phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen, cyano,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl,  $C_1-C_4$  alkoxy and  $C_1-C_4$  haloalkoxy, or  $R^8$  and  $R^9$  are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine ring;

$R^{10}$  is selected from the group consisting of H,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl,  $C_1-C_4$  alkoxyalkyl,  $C_3-C_6$  cycloalkyl,  $C_4-C_7$  cycloalkylalkyl,  $-C(O)R^{12}$ , phenyl and benzyl, wherein phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen,  $-NH_2$ ,  $-OH$ , cyano,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl,  $C_1-C_4$  alkoxy and  $C_1-C_4$  haloalkoxy;

$R^{11}$  is selected from the group consisting of H,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl,  $C_1-C_4$  alkoxyalkyl,  $C_3-C_6$  cycloalkyl,  $C_4-C_7$  cycloalkylalkyl, phenyl and benzyl, where phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen,  $-NH_2$ ,  $-OH$ ,

cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy, or R<sup>10</sup> and R<sup>11</sup> are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, N-methylpiperazine, morpholine, or thiomorpholine ring, with  
5 the proviso that only one of R<sup>8</sup> and R<sup>9</sup> or R<sup>10</sup> and R<sup>11</sup> are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine ring;

10 R<sup>12</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl and phenyl;

X is selected from the group consisting of O, NR<sup>13</sup> and S, with the proviso that X is not NR<sup>13</sup> when a compound is of  
15 Formula (IA);

n is 0, 1, or 2; and,

20 R<sup>13</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl and phenyl, wherein C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl and phenyl are optionally substituted with 1-3 substituents independently at each occurrence from halogen, -NH<sub>2</sub>, -OH, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy.


25 2. The compound of claim 1, wherein R<sup>1</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl.

3. The compound of claim 2, wherein R<sup>1</sup> is CH<sub>3</sub>.

4. The compound of claim 1, wherein  $R^2$  is H,  $C_1-C_6$  alkyl,  $C_3-C_6$  cycloalkyl, or  $C_1-C_6$  haloalkyl.
5. The compound of claim 4, wherein  $R^2$  is H or  $C_1-C_6$  alkyl.
6. The compound of claim 5, wherein  $R^2$  is H.
7. The compound of claim 1, wherein  $R^3$  is at each occurrence thereof independently H, halogen,  $C_1-C_6$  alkyl, or  $C_1-C_6$  alkyl substituted with from 1 to 3 of  $OR^8$  or  $NR^8R^9$ .
8. The compound of claim 7, wherein  $R^3$  is H or  $C_1-C_6$  alkyl.
9. The compound of claim 8, wherein  $R^3$  is H.
10. The compound of claim 1, wherein  $R^1$  is  $CH_3$ ,  $R^2$  is H and  $R^3$  is H.
11. The compound of claim 1, wherein  $R^4$ ,  $R^5$  and  $R^6$  are each independently H, halogen,  $C_1-C_6$  alkyl or  $-OR^{10}$ .
12. The compound of claim 11, wherein at least one of  $R^4$ ,  $R^5$  and  $R^6$  is H.
13. The compound of claim 12, wherein each of  $R^4$ ,  $R^5$  and  $R^6$  are H.
14. The compound of claim 12, wherein one of  $R^4$ ,  $R^5$  and  $R^6$  is halogen.

15. The compound of claim 1, wherein  $R^1$  is  $CH_3$ ,  $R^2$  and  $R^3$  are each H, and at least one of  $R^4$ ,  $R^5$  and  $R^6$  is H.

16. A compound of Formula (10) of claim 1:



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:


a compound of Formula (10) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;

a compound of Formula (10) wherein  $R^4$  is H,  $R^5$  is Me and  $R^6$  is H;

a compound of Formula (10) wherein  $R^4$  is Cl,  $R^5$  is H and  $R^6$  is H; and

a compound of Formula (10) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H.

17. A compound of Formula (20) of claim 1:



or a pharmaceutically acceptable salt form thereof selected  
5 from the group consisting essentially of:

a compound of Formula (20) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup>  
is H;


10 a compound of Formula (20) wherein R<sup>4</sup> is H, R<sup>5</sup> is Me and R<sup>6</sup>  
is H;

15 a compound of Formula (20) wherein R<sup>4</sup> is H, R<sup>5</sup> is Cl and R<sup>6</sup>  
is H;

a compound of Formula (20) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup>  
is H; and

20 a compound of Formula (20) wherein R<sup>4</sup> is F, R<sup>5</sup> is H and R<sup>6</sup>  
is F.

18. A compound of Formula (30) of claim 1:



or a pharmaceutically acceptable salt form thereof selected  
5 from the group consisting essentially of:

a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H  
and  $R^6$  is H;

a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is F  
and  $R^6$  is H;

a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H  
and  $R^6$  is F;

a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F  
and  $R^6$  is H;

a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is  
H and  $R^6$  is H;

a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is  
Cl and  $R^6$  is H;

a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is  
Cl and  $R^6$  is F;

a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F  
and  $R^6$  is Cl;




a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H  
and  $R^6$  is Cl;

a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is  
OMe and  $R^6$  is H; and

a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H  
and  $R^6$  is H.

19. A compound of Formula (40) of claim 1:



or a pharmaceutically acceptable salt form thereof selected  
from the group consisting essentially of:

a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H  
and  $R^6$  is H;

a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is F  
and  $R^6$  is H;

a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H  
and  $R^6$  is F;

a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H  
and  $R^6$  is H;

a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F  
and  $R^6$  is H;

5 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is  
H and  $R^6$  is H;

a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is  
Cl and  $R^6$  is H;

10 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is  
Cl and  $R^6$  is F;

5 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F  
and  $R^6$  is Cl;

a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H  
and  $R^6$  is Cl;


20 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is  
OMe and  $R^6$  is H;

a compound of Formula (40) wherein  $R^3$  is Me,  $R^4$  is H,  $R^5$  is  
H and  $R^6$  is H;

25 a compound of Formula (40) wherein  $R^3$  is Et,  $R^4$  is H,  $R^5$  is  
H and  $R^6$  is H; and

30 a compound of Formula (40) wherein  $R^3$  is  $CH_2OH$ ,  $R^4$  is H,  $R^5$   
is H and  $R^6$  is H.


20. A compound of Formula (50) of claim 1:



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (50) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H.

21. A compound of Formula (60) of claim 1:



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;

a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me;

a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Et;

5 a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is F and  $R^{13}$  is H;

a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is F and  $R^{13}$  is Me;

10 a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H,  $R^6$  is F and  $R^{13}$  is H;

15 a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H,  $R^6$  is F and  $R^{13}$  is Me;

a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;

20 a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me;

25 a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;

a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is H;


30 a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is Cl,  $R^6$  is H and  $R^{13}$  is H;

a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is Cl,  $R^6$  is H and  $R^{13}$  is Me;

35 a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is H; and

a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is Me.

5 22. A compound of Formula (70) of claim 1:



10 or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

15 a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;

20 a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me;

25 a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Et;

30 a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Bn;

a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is F and  $R^{13}$  is H;

a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is F and  $R^{13}$  is Me;

a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H,  $R^6$  is F and  $R^{13}$  is Me;

5 a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;

a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me;

10 a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;

a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me;

5 a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is H;


20 a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is Cl,  $R^6$  is H and  $R^{13}$  is H;

a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is Cl,  $R^6$  is H and  $R^{13}$  is Me;

25 a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is H; and

30 a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is Me.

23. A compound of Formula (80) of claim 1:



(80)


5 or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (80) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;

a compound of Formula (80) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is H; and

a compound of Formula (80) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is F.

24. A compound of Formula (90) of claim 1:



(90)


25 or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (90) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H.

a compound of Formula (90) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F; and

a compound of Formula (90) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H.


25. A compound of Formula (100) of claim 1:



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (100) wherein  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H.

26. A compound of Formula (110) of claim 1:





(110)

5 or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;

10 a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F;

a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;


a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is Cl;

a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;

a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl; and

25 a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H.

27. A compound of Formula (120) of claim 1:



(120)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

5 a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;

a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F;

10 a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;


a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is Cl;

5 a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;

20 a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H; and

25 a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl.

28. A compound of Formula (130) of claim 1:




30 or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (130) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H; and

5 a compound of Formula (130) wherein  $R^4$  is H,  $R^5$  is Bn and  $R^6$  is H.

10 29. A compound of Formula (140) of claim 1:



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

20 a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;

a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;

25 a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl;


a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;

30 a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is Cl;

a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H;

a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.

30. A compound of Formula (150) of claim 1:



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;

a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;

a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl;

a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;


a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is Cl;

a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H; and

a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.

5


31. A compound of Formula (160) of claim 1:



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (160) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H.

32. A compound of Formula (170) of claim 1:



25


or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (170) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;

a compound of Formula (170) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H; and

a compound of Formula (170) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.

33. A compound of Formula (180) of claim 1:



(180)


or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (180) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;

a compound of Formula (180) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H; and

a compound of Formula (180) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.

34. A compound of Formula (190) of claim 1:




(190)

5 or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

10 a compound of Formula (190) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H.

35. A compound of Formula (200) of claim 1:



(200)

15 or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

20 a compound of Formula (200) wherein R<sup>4</sup> is H, R<sup>5</sup> is H, R<sup>6</sup> is H and R<sup>13</sup> is H; and

25 a compound of Formula (200) wherein R<sup>4</sup> is H, R<sup>5</sup> is H, R<sup>6</sup> is H and R<sup>13</sup> is Me.

36. A compound of claim 1 selected from the group consisting of:

(R)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-  
h]isoquinoline;

(S)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-  
h]isoquinoline;

(R)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-  
g]isoquinoline;

(S)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-  
g]isoquinoline;

(R)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-h]isoquinoline;

(S)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-h]isoquinoline;

(R)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-h]isoquinoline;

(S)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-h]isoquinoline;

(R)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-  
h]isoquinoline;

(S)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-  
h]isoquinoline;

(R)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-h]isoquinoline;

(S)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-h]isoquinoline;

(R)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-  
h]isoquinoline;

(S)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-  
h]isoquinoline;



(R)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-*h*]isoquinoline;

(S)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-*h*]isoquinoline;

(R)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-*h*]isoquinoline;

(S)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-*h*]isoquinoline;

(R)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1*H*-pyrrolo[2,3-  
*h*]isoquinoline; and

(S)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1*H*-pyrrolo[2,3-  
*h*]isoquinoline.

37. A compound of claim 1 selected from the group consisting  
of:

(+)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-  
*h*]isoquinoline;

(-)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-  
*h*]isoquinoline;

(+)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-  
*g*]isoquinoline;

(-)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-  
*g*]isoquinoline;

(+)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-*h*]isoquinoline;

(-)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-*h*]isoquinoline;

(+)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-*h*]isoquinoline;

(-)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-*h*]isoquinoline;

(+)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-  
h]isoquinoline;

5 (-)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-  
h]isoquinoline;

(+)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-h]isoquinoline;

10 (-)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-h]isoquinoline;

(+)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-  
h]isoquinoline;

15 (-)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-  
h]isoquinoline;

(+)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-h]isoquinoline;

(-)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-h]isoquinoline;

25 (+)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-h]isoquinoline;

(-)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-  
furo[2,3-h]isoquinoline;

30 (+)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-  
h]isoquinoline; and

35 (-)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-  
h]isoquinoline.

38. A pharmaceutical composition comprising a  
pharmaceutically acceptable carrier and a therapeutically  
40 effective amount of a compound of claim 1.

39. A method of treating an animal afflicted with a  
neurological or psychological disorder selected from the group

consisting of attention deficit-hyperactivity disorder,  
anxiety, depression, post-traumatic stress disorder,  
supranuclear palsy, feeding disorders, obsessive compulsive  
disorder, analgesia, smoking cessation, panic attacks,  
5 Parkinson's and phobia, said method comprising administering  
to the animal the pharmaceutical composition of claim 38.

40. The method of claim 39 for treating attention deficit-  
hyperactivity disorder.

09902845 071101